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Product quality control without compromising productivity has been a major goal in biotherapeutics process 
development. The challenge is further increased for new modalities using complex and hybrid protein structures, 
such as nanobodies and bispecific antibodies.  New product-related impurities and unique product quality 
attribute (PQA) species have been found to accompany these new protein scaffolds, which usually don’t exist in 
standard mAb production.  Undesired attributes include unique patterns of glycosylation, conformation 
heterogeneity, mis-pairing, and partial molecules. Many of these PQAs are related to protein folding and 
assembly efficiency inside the cell, which impact post-translational modifications such as disulfide bond 
formation and glycosylation processes, directly or indirectly.  We have identified multiple intracellular causal 
factors that link some PQAs directly to host cell lineage. To improve understanding and increase options in 
developing a successful production cell line with desired product quality profile, we have used this information to 
develop diversified CHO host lineages using both conditioned-culture adaptation and CRISPR genome editing 
approaches. The resulting CHO hosts showed significant differences in cell growth and recombinant protein 
production, including productivity and quality attribute profiles.  Furthermore, the hosts respond differently to 
changes in medium components and process conditions. These differences were more significant for complex/ 
hybrid proteins such as nanobodies and bispecific antibodies.   OMICS tools were systematically utilized to 
identify the evolutionarily significance of genetic and epigenetic variability of individual host cell lineages, which 
determine the specific PQA profile of the expressed recombinant protein. Overall, our presentation will illustrate 
the importance of selecting the appropriate host cell line through screening and/or engineering, as part of quality 
control strategy to obtain the desired recombinant protein PQA profile.  .  
 
 
 
 
